{"id":5928,"date":"2010-03-15T12:32:32","date_gmt":"2010-03-15T16:32:32","guid":{"rendered":"http:\/\/asweetlife.org\/?p=5928"},"modified":"2015-12-28T08:12:08","modified_gmt":"2015-12-28T13:12:08","slug":"fda-requests-additional-information-from-mannkind-corp-regarding-afrezza","status":"publish","type":"post","link":"https:\/\/asweetlife.org\/?p=5928","title":{"rendered":"FDA Requests Additional Information From Mannkind Corp. Regarding AFREZZA"},"content":{"rendered":"<p><a href=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/03\/mnkd-mannkind-logo.jpg\" rel=\"mfp\"><img decoding=\"async\" class=\"alignleft size-full wp-image-5930 lazyload\" style=\"margin: 4px;\" title=\"mnkd-mannkind-logo\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" data-src=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/03\/mnkd-mannkind-logo.jpg\" alt=\"\" width=\"137\" height=\"64\" \/><\/a>MannKind Corporation <a href=\"http:\/\/www.news.mannkindcorp.com\/phoenix.zhtml?c=147953&amp;p=irol-newsArticle&amp;ID=1402294&amp;highlight=\" target=\"_blank\">announced<\/a> that it has received a Complete Response letter from the U.S. Food &amp; Drug Administration (FDA) regarding the New Drug Application (NDA) for AFREZZA(TM) \u00a0 Inhalation Powder for the treatment of adult patients with type 1 and type 2 diabetes.<\/p>\n<p>The Complete Response letter requested several items, including information and currently available clinical data that support the clinical utility of AFREZZA, and information about the comparability of the commercial version of the MedTone inhaler to the earlier version of this device that was used in pivotal clinical trials. The letter cited no safety concerns, but requested updated safety data related to AFREZZA. The letter also requested changes to the proposed labeling of the cartridges, foil pouches and cartons.<\/p>\n<p>The letter did not require any additional pre-marketing clinical studies in order for the FDA to complete its review of the NDA. As recommended by the FDA, MannKind will request an End-of-Review meeting with the agency to discuss its approach for resolving the remaining issues.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>MannKind Corporation announced that it has received a Complete Response letter from the U.S. Food &#038; Drug Administration (FDA) regarding the New Drug Application (NDA) for AFREZZA(TM)   Inhalation Powder for the treatment of adult patients with type 1 and type 2 diabetes&#8230;<\/p>\n","protected":false},"author":131,"featured_media":5930,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1441],"tags":[670,311],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.9 (Yoast SEO v22.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>FDA Requests Additional Information From Mannkind Corp. Regarding AFREZZA<\/title>\n<meta name=\"description\" content=\"MannKind Corporation announced that it has received a Complete Response letter from the U.S. FDA regarding the New Drug Application for AFREZZA\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/asweetlife.org\/?p=5928\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ASweetLife Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/asweetlife.org\/?p=5928\",\"url\":\"https:\/\/asweetlife.org\/?p=5928\",\"name\":\"FDA Requests Additional Information From Mannkind Corp. Regarding AFREZZA\",\"isPartOf\":{\"@id\":\"https:\/\/asweetlife.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/asweetlife.org\/?p=5928#primaryimage\"},\"image\":{\"@id\":\"https:\/\/asweetlife.org\/?p=5928#primaryimage\"},\"thumbnailUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/03\/mnkd-mannkind-logo.jpg\",\"datePublished\":\"2010-03-15T16:32:32+00:00\",\"dateModified\":\"2015-12-28T13:12:08+00:00\",\"author\":{\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\"},\"description\":\"MannKind Corporation announced that it has received a Complete Response letter from the U.S. FDA regarding the New Drug Application for AFREZZA\",\"breadcrumb\":{\"@id\":\"https:\/\/asweetlife.org\/?p=5928#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/asweetlife.org\/?p=5928\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/?p=5928#primaryimage\",\"url\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/03\/mnkd-mannkind-logo.jpg\",\"contentUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/03\/mnkd-mannkind-logo.jpg\",\"width\":137,\"height\":64,\"caption\":\"mannkind-logo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/asweetlife.org\/?p=5928#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/asweetlife.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Requests Additional Information From Mannkind Corp. Regarding AFREZZA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/asweetlife.org\/#website\",\"url\":\"https:\/\/asweetlife.org\/\",\"name\":\"ASweetLife\",\"description\":\"The Diabetes Magazine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/asweetlife.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\",\"name\":\"ASweetLife Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"caption\":\"ASweetLife Team\"},\"url\":\"https:\/\/asweetlife.org\/?author=131\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA Requests Additional Information From Mannkind Corp. Regarding AFREZZA","description":"MannKind Corporation announced that it has received a Complete Response letter from the U.S. FDA regarding the New Drug Application for AFREZZA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/asweetlife.org\/?p=5928","twitter_misc":{"Written by":"ASweetLife Team","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/asweetlife.org\/?p=5928","url":"https:\/\/asweetlife.org\/?p=5928","name":"FDA Requests Additional Information From Mannkind Corp. Regarding AFREZZA","isPartOf":{"@id":"https:\/\/asweetlife.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/asweetlife.org\/?p=5928#primaryimage"},"image":{"@id":"https:\/\/asweetlife.org\/?p=5928#primaryimage"},"thumbnailUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/03\/mnkd-mannkind-logo.jpg","datePublished":"2010-03-15T16:32:32+00:00","dateModified":"2015-12-28T13:12:08+00:00","author":{"@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585"},"description":"MannKind Corporation announced that it has received a Complete Response letter from the U.S. FDA regarding the New Drug Application for AFREZZA","breadcrumb":{"@id":"https:\/\/asweetlife.org\/?p=5928#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/asweetlife.org\/?p=5928"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/?p=5928#primaryimage","url":"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/03\/mnkd-mannkind-logo.jpg","contentUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/03\/mnkd-mannkind-logo.jpg","width":137,"height":64,"caption":"mannkind-logo"},{"@type":"BreadcrumbList","@id":"https:\/\/asweetlife.org\/?p=5928#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/asweetlife.org\/"},{"@type":"ListItem","position":2,"name":"FDA Requests Additional Information From Mannkind Corp. Regarding AFREZZA"}]},{"@type":"WebSite","@id":"https:\/\/asweetlife.org\/#website","url":"https:\/\/asweetlife.org\/","name":"ASweetLife","description":"The Diabetes Magazine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/asweetlife.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585","name":"ASweetLife Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","caption":"ASweetLife Team"},"url":"https:\/\/asweetlife.org\/?author=131"}]}},"_links":{"self":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/5928"}],"collection":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5928"}],"version-history":[{"count":0,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/5928\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/media\/5930"}],"wp:attachment":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5928"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5928"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5928"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}